Turns out the lights on Steglatro

[anonymous]

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure
https://www.ajmc.com/conferences/ad...-cv-outcomes-despite-promise-in-heart-failure

 

[anonymous]

I don’t think CNN or Fox News could spin this one!

 

[anonymous]

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure
https://www.ajmc.com/conferences/ad...-cv-outcomes-despite-promise-in-heart-failure

This study will be the death of Steglatro and possibly the chronic care sales force. They do not need a sales force to sell Januvia and Steglatro will not be able to compete with its peers.

 

[anonymous]

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure
https://www.ajmc.com/conferences/ad...-cv-outcomes-despite-promise-in-heart-failure

This study will be the death of Steglatro and possibly the chronic care sales force. They do not need a sales force to sell Januvia and Steglatro will not be able to compete with its peers.

 

[anonymous]

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure
https://www.ajmc.com/conferences/ad...-cv-outcomes-despite-promise-in-heart-failure

This trial will be the death of Steglatro and possibly the death of the chronic care sales force. They do not need a sales force to sell Januvia and Steglatro officially has no chance to compete against its peers